Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2021

Open Access 01-03-2021 | Vasculitis | Review Article

Skin changes in hairy cell leukemia

Authors: Ewa Robak, Dorota Jesionek-Kupnicka, Tadeusz Robak

Published in: Annals of Hematology | Issue 3/2021

Login to get access

Abstract

Skin lesions have been reported in about 10–12% of hairy cell leukemia (HCL) patients. Most are etiologically related to autoimmune or infectious processes, although secondary cutaneous neoplasms and drug-induced lesions are also reported. However, leukemia cutis with the direct infiltration of the skin by leukemic cells is extremely rare in HCL patients. This paper reviews the epidemiology, pathogenesis, clinical symptoms, diagnosis, and approach to treating skin lesions in HCL. A literature review of the MEDLINE database for articles in English concerning hairy cell leukemia, skin lesions, leukemia cutis, adverse events, infectious, cutaneous, drug reactions, neutrophilic dermatoses, secondary neoplasms, and vasculitis was conducted via PubMed. Publications from January 1980 to September 2020 were scrutinized. Additional relevant publications were obtained by reviewing the references from the chosen articles.
Literature
1.
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129(5):553–560PubMedPubMedCentral
2.
Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C, ESMO Guidelines Committee (2015) Hairy cell leukaemia: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v100–v107PubMed
3.
Teras LR, Desantis DE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443–459PubMed
4.
Bernstein L, Newton P, Ross RK (1990) Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 50(12):3605–3609PubMed
5.
Kristinsson SY, Vidarsson B, Agnarsson BA, Haraldsdottir V, Olafsson O, Johannesson GM, Eyjolfsson GI, Bjornsdottir J, Onundarson PT, Reykdal S (2002) Epidemiology of hairy cell leukemia in Iceland. Hematol J 3(3):145–147PubMed
6.
Polliack A (2002) Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 6(4):366–388PubMed
7.
Tadmor T, Polliack A (2011) Unusual clinical manifestations, rare sites of involvement, and the association of other disorders with hairy cell leukemia. Leuk Lymphoma 52(Suppl 2):57–61PubMed
8.
9.
Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322(16):1117–1721PubMed
10.
Chandran R, Gardiner SK, Smith SD, Spurgeon SE (2013) Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 163(3):407–409PubMed
11.
Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O'Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D (2009) Long-term follow-up of 233 patients with hairy cell leukaemia treated initially with pentostatin or cladribine at a median of 16 years. Br J Haematol 145(6):733–740PubMed
12.
Sigal DS, Sharpe R, Burian C, Saven A (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 115(10):1893–1896PubMed
13.
Baer MR, Ozer H, Foon KA (1992) Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 81(2):167–169PubMed
14.
Habermann TM, Rai K (2011) Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma 52(Suppl 2):18–20PubMed
15.
Seymour JF, Estey EH, Keating MJ, Kurzrock R (1995) (1995) Response to interferon-α in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 9(5):929–932PubMed
16.
Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A (2015) Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. Ann Hematol 94(1):89–95PubMed
17.
Thomas DA, O’Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood 102(12):3906–3911PubMed
18.
Nieva J, Bethel K, Saven A (2003) Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102(3):810–813PubMed
19.
Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F (2016) Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174(5):760–766PubMedPubMedCentral
20.
Robak T, Wolska A, Robak P (2015) Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opin Investig Drugs 24(11):1419–1431PubMed
21.
Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F (2018) Moxetumomab pasudotox in relapsed/ refractory hairy cell leukemia. Leukemia 32(8):1768–1777PubMedPubMedCentral
22.
Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733–1747PubMedPubMedCentral
23.
Vergote V, Dierickx D, Janssens A, Verhoef G, Tousseyn T, Vandenberghe P, Wolter P, Delforge M (2014) Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Ann Hematol 93(12):2087–2089PubMed
24.
Cannon T, Mobarek D, Wegge J, Tabbara IA (2008) Hairy cell leukemia: current concepts. Cancer Investig 26(8):860–865
25.
Carsuzaa F, Pierre C, Jaubert D, Viala JJ (1994) Cutaneous findings in hairy cell leukemia. Review of 84 cases. Nouv Rev Fr Hematol 35(6):541–543PubMed
26.
Colović N, Perunicić M, Jurisić V, Colović M (2010) Specific skin lesions in hairy cell leukemia at presentation: case report and review of literature. Med Oncol 27(2):559–561PubMed
27.
Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F (2008) Leukemia cutis. Am J Clin Pathol 129(1):130–142PubMed
28.
Robak E, Robak T (2007) Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma 48(5):855–865PubMed
29.
Arai E, Ikeda S, Itoh S, Katayama I (1988) Specific skin lesions as the presenting symptom of hairy cell leukemia. Am J Clin Pathol 90(4):459–464PubMed
30.
Bilsland D, Shahriari S, Douglas WS, Chaudhuri AK, Todd WT (1991) Transient leukaemia cutis in hairy-cell leukaemia. Clin Exp Dermatol 16(3):207–209PubMed
31.
Lawrence DM, Sun NCJ, Mena R, Moss R (1983) Cutaneous lesions in hairy cell leukemia. Case report and review of the literature. Arch Dermatol 119(4):322–325PubMed
32.
Fressoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, Dini E, Resegotti L, Damasio EE, Silingardi V (1994) Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Leuk Lymphoma 13(3–4):307–316
33.
Finan MC, Su WP, Li CY (1998) Cutaneous findings in hairy cell leukemia. J Am Acad Dermatol 11(5 Pt 1):788–797
34.
Parsi M, Go MS, Ahmed A (2020) Cancer, leukemia cutis. 2020 Aug 8. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2020 Jan.
35.
Ergene U, Ozbalcı D, Işisağ A (2012) Hairy cell leukemia and cutaneous involvement. Transfus Apher Sci 46(2):231–232PubMed
36.
Fino P, Fioramonti P, Onesti MG, Passaretti D, Scuderi N (2012) Skin metastasis in patient with hairy cell leukemia: case report and review of literature. In Vivo 26(2):311–314PubMed
37.
Dearden CE, Else M, Catovsky D (2011) Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 52(suppl 2):21–24PubMed
38.
Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM (1998) Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 92(4):1160–1164PubMed
39.
Saven A, Burian C, Koziol JA, Piro LD (1992) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 6:1918–1926
40.
Kurzrock R, Strom SS, Estey E, O’Brien S, Keating MJ, Jiang H, Adams T, Talpaz M (1997) Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 15(5):1803–1810PubMed
41.
Hisada M, Chen BE, Jaffe ES, Travis LB (2007) Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 99(3):215–222PubMed
42.
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Mey U, Blum S, Rauch D, O’Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Li Q, Feller A, Stussi G (2020) Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Adv 4(15):3699–3707PubMedPubMedCentral
43.
da Silva WF, Neto AC, da Rosa LI, de Siqueira IA, Amarante GD, Velloso EDRP, Rego EM, Rocha V, Buccheri V (2019) Outcomes and second neoplasms in hairy cell leukemia: a retrospective cohort. Leuk Res 83:106165PubMed
44.
Schön MP, Reifenberger J, Von Schmiedeberg S, Megahed M, Lang K, Gattermann N, Meckenstock G, Goerz G, Ruzicka T (1999) Multiple basal cell carcinomas associated with hairy cell leukaemia. Br J Dermatol 140(1):150–153PubMed
45.
Watts JM, Kishtagari A, Hsu M, Lacouture ME, Postow MA, Park JH, Stein EM, Teruya-Feldstein J, Abdel-Wahab O, Devlin SM, Tallman MS (2015) Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. Br J Haematol 171(1):84–90PubMedPubMedCentral
46.
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3):207–215
47.
Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK (2013) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18(3):314–322PubMedPubMedCentral
48.
Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30(19):2375–2383PubMedPubMedCentral
49.
Robert C, Arnault JP, Mateus C (2011) RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23(2):177–182PubMed
50.
Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30(3):316–321PubMed
51.
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703PubMedPubMedCentral
52.
Kreitman RJ, Moreau P, Hutchings M, Gazzah A, Blayn JY, Wainberg ZA, Stein A, Dietrich S, de Jonge MJA, Willenbacher W, De Greve J, Arons E, Ravandi F, Rangwala F, Burgess P, Mookerjee B, Subbiah V (2018) Treatment with combination of dabrafenib and trametinib in patients with recurrent/refractory BRAF V600E-mutated hairy cell leukemia (HCL). Blood 132 Abstract 391
53.
Caeser R, Collord G, Yao WQ, Chen Z, Vassiliou GS, Beer PA, Du MQ, Scott MA, Follows GA, Hodson DJ (2019) Targeting MEK in vemurafenib resistant hairy cell leukemia. Leukemia. 33(2):541–545PubMed
54.
Bhangoo MS, Saven A (2019) Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia. Leuk Lymphoma 60(5):1331–1333PubMed
55.
Zheng G, Chattopadhyay S, Sud A, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K (2019) Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. Br J Haematol 185(2):232–239PubMed
56.
Paolini R, Poletti A, Ramazzina E, Menin C, Santacatterina M, Montagna M, Bonaldi L, Del Mistro A, Zamboni S, D’Andrea E (2000) Co-existence of cutaneous T-cell lymphoma and B hairy cell leukemia. Am J Hematol 64(3):197–202PubMed
57.
Hallermann C, Kaune MK, Tiemann M, Kunze E, Griesinger F, Mitteldorf C, Bertsch HP, Neumann C (2007) High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol 86(7):509–515PubMed
58.
Wong E, Mahmood MN, Salopek TG (2017) Concomitant B hairy cell leukemia and mycosis fungoides in an elderly man. Case Rep Dermatol 9(1):103–107PubMedPubMedCentral
59.
Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E (2006) Mycosis fungoides associated with B-cell malignancies. Br J Dermatol 2155(2):379–386
60.
Wulf GG, Schulz H, Hallermann C, Kunze E, Wörmann B (2001) Reactive polyclonal T-cell lymphocytosis mimicking Sezary syndrome in a patient with hairy cell leukemia. Haematologica. 86(10):E27PubMed
61.
Prakash A, Khalafallah AA (2018) Concurrent hairy cell leukemia and metastatic merkel cell carcinoma. Case Rep Oncol Med 2018:1736854PubMedPubMedCentral
62.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11PubMed
63.
Wooten MD, Jasin HE (1996) Vasculitis and lymphoproliferative diseases. Semin Arthritis Rheum 26(2):564–574PubMed
64.
Gulati S, Patel NP, Swierczynski SL (2012) Vasculitides associated with haematological malignancies: a case-based review. BMJ Case Rep 2012:bcr2012007123PubMedPubMedCentral
65.
Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Blétry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L (2007) Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 57(8):1473–1480PubMed
66.
Grey MR, Flanagan NG, Kelsey PR (2000) Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin Lab Haematol 22(2):111–113PubMed
67.
Broccoli A, Gandolfi L, Pellegrini C, Agostinelli C, Argnani L, Zinzani PL (2016) Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: a case report and review of the literature. Tumori 102(Suppl. 2). https://​doi.​org/​10.​5301/​tj.​5000487
68.
Gabriel SE, Conn DL, Phyliky RL, Scott RE (1986) Vasculitis in hairy cell leukaemia: review of literature and consideration of possible pathogenic mechanisms. J Rheumatol 13(6):1167–1172PubMed
69.
Hasler P, Kistler H, Gerber H (1995) Vasculitides in hairy cell leukemia. Semin Arthritis Rheum 25(2):134–142PubMed
70.
Remkova A, Halcín A, Stenová E, Babál P, Kasperová V, Vranovský A (2007) Acute vasculitis as a first manifestation of hairy cell leukemia. Eur J Intern Med 18(3):238–240PubMed
71.
Audemard A, Crochette R, Salaün V, Comoz F, Ficheux M (2014) IgA vasculitis revealing hairy cell leukemia relapse treated by cladribine. Presse Med 43(3):321–323PubMed
72.
Moyers JT, Liu LW, Ossowski S, Goddard L, Kamal MO, Cao H (2019) A rash in a hairy situation: leukocytoclastic vasculitis at presentation of hairy cell leukemia. Am J Hematol 94(12):1433–1434PubMed
73.
Farcet JP, Weschsler J, Wirquin V, Divine M, Reyes F (1987) Vasculitis in hairy cell leukemia. Arch Intern Med 147(4):660–664PubMed
74.
Westbrook CA, Golde DW (1985) Autoimmune disease in hairy cell leukaemia: clinical syndromes and treatment. Br J Haematol 61(2):349–356PubMed
75.
Tousi B, D’Silva R, Papish S (2002) Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine. Clin Lab Haematol 24(4):259–260PubMed
76.
Seshadri P, Hadges S, Cropper T (2000) Acute necrotising vasculitis in hairy cell leukemia—rapid response to cladribine: case report and a brief review of the literature. Leuk Res 24(9):791–793PubMed
77.
International Study Group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080
78.
Oo TH, Delafuente M, Hassoun H (2003) Possible association between hairy cell leukemia and Behçet’s disease. South Med J 96(3):323–324PubMed
79.
Oksuz MF, Coskun BN, Tufan AN, Orucoglu N, Dalkilic E, Oztürk Nazlıoğlu H, Pehlivan Y (2014) Hairy cell leukemia presenting initially with symptoms of Behçet’s disease. Int J Rheum Dis 17(6):689–692PubMed
80.
Weinstein AJ (1982) Systemic vasculitis and hairy cell leukemia. J Rheumatol 9(3):349–350PubMed
81.
Carpenter MT, West SG (1994) Polyarteritis nodosa in hairy cell leukemia: treatment with interferon-alpha. J Rheumatol 21(6):1150–1152PubMed
82.
Ozkok A, Elcioglu OC, Akpinar TS, Nalcaci M (2011) Vasculitis in a patient with hairy cell leukemia. Intern Med 50(21):2713PubMed
83.
Vankalakunti M, Joshi K, Jain S, Nada R, Radotra BD, Varma S (2007) Polyarteritis nodosa in hairy cell leukaemia: an autopsy report. J Clin Pathol 60(10):1181–1182PubMedPubMedCentral
84.
Komadina KH, Houk RW (1989) Polyarteritis nodosa presenting as recurrent pneumonia following splenectomy for hairy-cell leukemia. Semin Arthritis Rheum 18(4):252–257PubMed
85.
86.
Ventura F, Rocha J, Pereira T, Marques H, Pardal F, Brito C (2009) Sweet syndrome as the presenting symptom of hairy cell leukemia. Dermatol Online J 15(2):12PubMed
87.
Levy RM, Junkins-Hopkins JM, Turchi JJ, James WD (2002) Sweet syndrome as the presenting symptom of relapsed hairy cell leukemia. Arch Dermatol 138(12):1551–1554PubMed
88.
Dalrì P, Boi S, Cristofolini M, Piscioli F, Rubertelli M (1982) Sweet syndrome: presenting symptom of hairy cell leukemia with fatal infection by Pneumocystis carinii. Haematologica. 67(5):765–768PubMed
89.
Alkayem M, Cheng W (2014) A case report of hairy cell leukemia presenting concomitantly with sweet syndrome. Case Rep Med 2014:823286PubMedPubMedCentral
90.
Gisser SD (1983) Acute febrile neutrophilic dermatosis (Sweet’s syndrome) in a patient with hairy-cell leukemia. Am J Dermatopathol 5(3):283–288PubMed
91.
Shah PR, Scott G, Beck LA (2019) Image gallery: hairy-cell leukaemia presenting with Sweet syndrome. Br J Dermatol 180(1):e3PubMed
92.
Özdoğu H, Yeral M, Boğa C (2017) An unusual giant leg ulcer as a rare presentation of Sweet’s syndrome in a patient with hairy cell leukemia successfully managed by splenectomy. Turk J Haematol 34(3):270–271PubMedPubMedCentral
93.
Kromer C, Schön MP, Buhl T (2020) Sweet’s syndrome as precursor of hairy cell leukemia. Dtsch Arztebl Int 117(10):176PubMedPubMedCentral
94.
George C, Deroide F, Rustin M (2019) (1019) Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med (Lond) 19(3):224–228
95.
Janowska A, Oranges T, Fissi A, Davini G, Romanelli M, Dini V (2020) PG-TIME: a practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther 33(3):e13412PubMed
96.
Kaplan RP, Newman G, Saperia D (1987) Pyoderma gangrenosum and hairy cell leukemia. J Dermatol Surg Oncol 13(9):1029–1031PubMed
97.
Jain A, Lad D, Prakash G, Khadwal A, Malhotra P, Bal A, Mallik N, Kumar N, Varma S (2017) Bullous pyoderma gangrenosum associated with hairy cell leukemia and its complete response to cladribine therapy. Indian J Hematol Blood Transfus 33(2):273–275PubMed
98.
Tombak A, Aygun S, Serinsoz E, Tiftik EN (2015) Complete recovery of pyoderma gangrenosum after successful treatment of underlying hairy cell leukemia with cladribine. Korean J Intern Med 30(5):739–741PubMedPubMedCentral
99.
Svecová D, Pallová A, Chmurová N, Babal P (2018) Paraneoplastic vasculitis associated with hairy cell leukemia. Prague Med Rep 109(1):83–87
100.
Finan MC, Su WP, Li CY (1984) Cutaneous findings in HCL. J Am Acad Dermatol 11(5 Pt 1):788–797PubMed
101.
Filho RJ, de Carvalho PN, Neto AM, Teixeira Henderson MN, Pinheiro RF (2011) Nontuberculous mycobacterium genital infection mimicking donovanosis in a patient with hairy cell leukemia. Leuk Res 35(5):e44–e45PubMed
102.
Weinstein RA, Golomb HM, Grumet G, Gelmann E, Schechter GP (1981) Hairy cell leukemia: association with disseminated atypical mycobacterial infection. Cancer 48(2):380–383PubMed
103.
Trizna Z, Tschen J, Natelson EA (2001) Atypical mycobacterial infection in a patient with hairy cell leukemia. Cutis. 67(3):241–242PubMed
104.
Castor B, Juhlin I, Henriques B (1994) Septic cutaneous lesions caused by Mycobacterium malmoense in a patient with hairy cell leukemia. Eur J Clin Microbiol Infect Dis 13(2):145–148PubMed
105.
Maurice PD, Bunker C, Giles F, Goldstone A, Holton J (1988) Mycobacterium avium-intracellular infection associated with hairy-cell leukemia. Arch Dermatol 124(10):1545–1549PubMed
106.
Kumar S, Kumar D, Gourley WK, Alperin JB (1994) Sporotrichosis as a presenting manifestation of hairy cell leukemia. Am J Hematol 46(2):134–137PubMed
107.
Salata RA, King RE, Gose F, Pearson RD (1986) Listeria monocytogenes cerebritis, bacteremia, and cutaneous lesions complicating hairy cell leukemia. Am J Med 81(6):1068–1072PubMed
108.
Bettens S, Delaere B, Glupczynski Y, Schoevaerdts D, Swine C (2008) Ecthyma gangrenosum in a non-neutropaenic, elderly patient: case report and review of the literature. Acta Clin Belg 63:394–397PubMed
109.
Sluga R, Tersmette M, Sohne M (2019) Hairy cell leukemia presenting with Ecthyma Gangrenosum- a case report. BMC Infect Dis 19(1):85PubMedPubMedCentral
110.
Ganzel C, Gatt ME, Maly A, Ben-Yehuda D, Goldschmidt N (2012) High incidence of skin rash in patients with hairy cell leukemia treated with cladribine. Leuk Lymphoma 53(6):1169–1173PubMed
111.
Meher-Homji Z, Tam CS, Siderov J, Seymour JF, Holmes NE, Chua KYL, Phillips EJ, Slavin MA, Trubiano JA (2019) High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing. Leuk Lymphoma 60(14):3455–3460PubMedPubMedCentral
112.
Cohen PR, Kurzrock R (1999) 2-chloro-deoxyadenosine-associated transient acantholytic dermatosis in hairy cell leukemia patients. Am J Dermatopathol 21(1):106–108PubMed
113.
Chubar Y, Bennett M (2003) Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. Br J Haematol 122(5):768–770PubMed
114.
Espinosa Lara P, Quirós Redondo V, Aguado Lobo M, Jiménez-Reyes J (2017) Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol. Ann Hematol 96(7):1209–1210PubMed
115.
Castagna J, Amsler E, Kurihara F, Chasset F, Barbaud A, Soria A (2020) Atypical features of cutaneous adverse drug reactions during therapy for hairy cell leukemia. J Allergy Clin Immunol Pract S2213-2198(20):30600–30600
116.
Zevin S, Hershko C, Rosenmann E (1996) Halogenoderma of the forearm caused by 2-chlorodeoxyadenosine treatment. Am J Hematol 53(3):209–210PubMed
117.
Li C, Geng H, Ji L, Jiang Y, Ma X, Yin Q, Xiong H (2019) Severe polymorphic erythema due to interferon α-2b during treatment of hairy cell leukemia. J Int Med Res 47(7):3453–3457PubMedPubMedCentral
118.
Urosevic-Maiwald M, Nobbe S, Kerl K, Benz R (2014) Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment- or disease-related? J Dermatol 41(4):329–333PubMed
119.
Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P (2015) Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol 151(10):1103–1109PubMed
120.
Tiacci E, De Carolis L, Simonetti E, Zaja F, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani P, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Visani G, Foa R, Falini B (2019) The BRAF inhibitor vemurafenib plus rituximab produces a high rate of deep and durable responses in relapsed/refractory hairy cell leukemia: updated results of a phase-2 trial. Hematol Oncol 37(S2):110–111
121.
122.
Singh AG, Tchanque-Fossuo CN, Elwood H, Durkin JR (2020) BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis. Dermatol Online J 26(2):13030/qt3ps33564PubMed
Metadata
Title
Skin changes in hairy cell leukemia
Authors
Ewa Robak
Dorota Jesionek-Kupnicka
Tadeusz Robak
Publication date
01-03-2021
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-04349-z

Other articles of this Issue 3/2021

Annals of Hematology 3/2021 Go to the issue

Original Article

G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?

Original Article

Correction of iron deficiency in hospitalized heart failure patients does not improve patient outcomes

Letter to the Editor

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan

Original Article

Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level

Original Article

Watch-and-wait or immediate immunotherapy/immunochemotherapy in patients with phase IE primary pulmonary MALT lymphoma? A multicenter retrospective study

Original Article

Effects of three months of treatment with vitamin E and N-acetyl cysteine on the oxidative balance in patients with transfusion-dependent β-thalassemia

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits